Jonathan Krell, Danielle Shaw, John McGrane, Andreas Hartkopf, Ana Herrero, Cheng Yeoh, Maria Masvidal, Francesco Raspagliesi, Whitney York, Jeanne M Schilder, Barbara Mascialino, Eleanor McDermott, Linda Kalilani, Lars Hanker
{"title":"欧洲卵巢癌回顾性研究（O'CaRE）：按进展风险因素数量分列的一线治疗结果。","authors":"Jonathan Krell, Danielle Shaw, John McGrane, Andreas Hartkopf, Ana Herrero, Cheng Yeoh, Maria Masvidal, Francesco Raspagliesi, Whitney York, Jeanne M Schilder, Barbara Mascialino, Eleanor McDermott, Linda Kalilani, Lars Hanker","doi":"10.1080/14796694.2024.2402217","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> The Ovarian Cancer Retrospective European (O'CaRE) study assessed the cumulative impact of high-risk factors on progression-free survival (PFS) and overall survival (OS) following first-line treatment in patients diagnosed with advanced ovarian cancer.<b>Patients & methods:</b> Medical records were collected from five European countries (2014 and 2015). Patients were grouped by number of high-risk factors: stage IV diagnosis, no known <i>BRCA mutation</i>, interval debulking surgery or no surgery, or visible residual disease.<b>Results:</b> Our analysis included 405 patients grouped based on having one (20.4%); two (32.3%); three (33.7%) or four (11.9%) high-risk factors. Increasing cumulative numbers of high-risk factors were associated with numerically shorter PFS and OS.<b>Conclusion:</b> Risk profiles should be carefully considered when planning clinical care.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-11"},"PeriodicalIF":3.0000,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ovarian Cancer Retrospective European (O'CaRE) study: first-line outcomes by number of risk factors for progression.\",\"authors\":\"Jonathan Krell, Danielle Shaw, John McGrane, Andreas Hartkopf, Ana Herrero, Cheng Yeoh, Maria Masvidal, Francesco Raspagliesi, Whitney York, Jeanne M Schilder, Barbara Mascialino, Eleanor McDermott, Linda Kalilani, Lars Hanker\",\"doi\":\"10.1080/14796694.2024.2402217\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Aim:</b> The Ovarian Cancer Retrospective European (O'CaRE) study assessed the cumulative impact of high-risk factors on progression-free survival (PFS) and overall survival (OS) following first-line treatment in patients diagnosed with advanced ovarian cancer.<b>Patients & methods:</b> Medical records were collected from five European countries (2014 and 2015). Patients were grouped by number of high-risk factors: stage IV diagnosis, no known <i>BRCA mutation</i>, interval debulking surgery or no surgery, or visible residual disease.<b>Results:</b> Our analysis included 405 patients grouped based on having one (20.4%); two (32.3%); three (33.7%) or four (11.9%) high-risk factors. Increasing cumulative numbers of high-risk factors were associated with numerically shorter PFS and OS.<b>Conclusion:</b> Risk profiles should be carefully considered when planning clinical care.</p>\",\"PeriodicalId\":12672,\"journal\":{\"name\":\"Future oncology\",\"volume\":\" \",\"pages\":\"1-11\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-10-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14796694.2024.2402217\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2024.2402217","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Ovarian Cancer Retrospective European (O'CaRE) study: first-line outcomes by number of risk factors for progression.
Aim: The Ovarian Cancer Retrospective European (O'CaRE) study assessed the cumulative impact of high-risk factors on progression-free survival (PFS) and overall survival (OS) following first-line treatment in patients diagnosed with advanced ovarian cancer.Patients & methods: Medical records were collected from five European countries (2014 and 2015). Patients were grouped by number of high-risk factors: stage IV diagnosis, no known BRCA mutation, interval debulking surgery or no surgery, or visible residual disease.Results: Our analysis included 405 patients grouped based on having one (20.4%); two (32.3%); three (33.7%) or four (11.9%) high-risk factors. Increasing cumulative numbers of high-risk factors were associated with numerically shorter PFS and OS.Conclusion: Risk profiles should be carefully considered when planning clinical care.
期刊介绍：
Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community.
The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
